Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/5023756_CN23756_0